Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Inclusion Criteria: * Pathologically confirmed cancer, meeting 1 of the following criteria: * Disease that has progressed on standard therapy * Locally advanced but unresectable primary or recurrent solid tumor * Metastatic disease, including previously untreated metastatic disease for which study regimen represents reasonable initial chemotherapy with palliative intent (e.g., metastatic gastric cancer, hepatobiliary cancer, or cancer for which no effective standard therapy exists) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count ≥ 2,000/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) ≤ 2.5 times ULN * Creatinine ≤ 1.6 mg/dL * Left ventricular ejection fraction ≥ 50% * Fertile patients must use effective contraception * Recovered from prior therapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) or immunotherapy * At least 2 weeks since prior radiotherapy * At least 8 weeks since prior strontium therapy * At least 4 weeks since prior and no concurrent sorivudine or brivudine Exclusion Criteria: * No other potentially curative treatment options available (e.g., surgery, radiotherapy, chemoradiotherapy, or combination chemotherapy) * No leukemia or lymphoma * No primary central nervous system (CNS) malignancies or CNS metastases * No other medical illness that would preclude study…